Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322468 | 1.00 | BTK (0.53) | BTKBRD4PIK3CDUSP30PIK3CA | |
| SCHEMBL323067 | 0.82 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL322507 | 0.82 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL322273 | 0.79 | C5AR1 (0.43) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL322844 | 0.77 | BTK (0.53) | BTKPIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL322843 | 0.77 | BTK (0.53) | BTKPIK3CDUSP30PIK3CAPIK3CB | |
| SCHEMBL19350217 | 0.77 | PIK3CD (0.42) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL322619 | 0.75 | PIK3CD (0.75) | PIK3CDPIK3CAPIK3CBHTR2BPIK3CG | |
| SCHEMBL322620 | 0.75 | PIK3CD (0.75) | PIK3CDPIK3CAPIK3CBHTR2BPIK3CG | |
| SCHEMBL21385394 | 0.75 | GRM5 (0.47) | ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-20180265509-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2018-09-20 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| EP-2590974-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013001445-A1 | SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013001445-A1 | SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-03 | — | — | WO | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885BRD4 1479/4885PIK3CD 6/4885 |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885BRD4 1479/4885PIK3CD 6/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885BRD4 1479/4885PIK3CD 6/4885 |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885BRD4 1479/4885PIK3CD 6/4885 |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885BRD4 1479/4885PIK3CD 6/4885 |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | PIK3CA, PIK3CD, PIK3CB | BTK 97/4885BRD4 2032/4885PIK3CD 2/4885 |
| US-20180265509-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | BTK 150/4885BRD4 1479/4885PIK3CD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.